Find clinical trials for Endometrial Cancer in London, England
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Endometrial Cancer trials near London, England, GBR:
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to p...
Phase 3
London, United Kingdom and 318 other locations
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...
Phase 3
London, United Kingdom and 253 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
London, London, City of, United Kingdom and 243 other locations
study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial...
Phase 3
London, United Kingdom and 100 other locations
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared ...
Phase 3
London, United Kingdom and 45 other locations
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth f...
Phase 3
London, United Kingdom and 190 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
London, United Kingdom and 168 other locations
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer...
Phase 3
London, United Kingdom and 188 other locations
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advance...
Phase 3
London, Surrey, United Kingdom and 265 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Phase 1
London, United Kingdom and 30 other locations
Clinical trials
Research sites
Resources
Legal